AssetMark Inc’s Voyager Therapeutics VYGR Stock Holding History

AssetMark Inc’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-44	Closed	–	–	1560
2021 Q1	$0	Hold	44	–	–	﹤0.01%	1551
2020 Q4	$0	Buy	44 +11	+33%	+$106	﹤0.01%	1500
2020 Q3	$0	Hold	33	–	–	﹤0.01%	1409
2020 Q2	$0	Sell	33 -7	-18%	-$81	﹤0.01%	1453
2020 Q1	$0	Sell	40 -18	-31%	-$207	﹤0.01%	1550
2019 Q4	$1K	Hold	58	–	–	﹤0.01%	1345
2019 Q3	$1K	Buy	+58	New	+$1.22K	﹤0.01%	1269

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AssetMark Inc's VYGR Position: Q2 2021 in Review

AssetMark Inc sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 44 shares.

AssetMark Inc first reported a position in VYGR in Q3 2019 and held it in 7 quarters. The position peaked at $1K in Q4 2019. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

AssetMark Inc reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
AssetMark Inc sold 44 Voyager Therapeutics shares in Q2 2021.
AssetMark Inc first reported a position in Voyager Therapeutics in Q3 2019 and held it in 7 quarters.
AssetMark Inc's Voyager Therapeutics position peaked at $1K in Q4 2019.
78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on AssetMark Inc's 13F filing for Q2 2021, filed 16 Aug 2021.